Summit Therapeutics Says Accepted Offers From Multiple Investors To Purchase Aggregate Of 10.35M Shares At $22.70 Per Share For Aggregate Gross Proceeds Of $235M
Summit Therapeutics Says Accepted Offers From Multiple Investors To Purchase Aggregate Of 10.35M Shares At $22.70 Per Share For Aggregate Gross Proceeds Of $235M
summit therapeutics表示已接受多家投资者购买总计1035万股股票,每股价格为22.70美元,总交易金额为2.35亿美元。
All of Summit's Section 16 officers participated in the capital raise. A total of $79 million was raised by insiders, including Robert W. Duggan, Dr. Maky Zanganeh, Manmeet S. Soni, and Bhaskar Anand, as well as Jeff Huber, a member of the Board of Directors, who invested via a controlled entity. The remaining $156 million was raised with multiple leading biopharma institutional investors.
所有Summit的第16条款的高级管理人员参与了资本筹集活动。内部人士筹集了总共$79,000,000,包括Robert W. Duggan、Dr. Maky Zanganeh、Manmeet S. Soni和Bhaskar Anand,以及董事会成员Jeff Huber通过受控实体进行投资。其余的$156,000,000由多家主要生物制药机构投资者筹集。